5-(2-呋喃)异恶唑-3-甲酸 | 98434-06-1

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(2-呋喃)异恶唑-3-甲酸
• 中文别名: 5-(2-呋喃)异唑-3-甲酸
• 英文名称: 5-(furan-2-yl)-1,2-oxazole-3-carboxylic acid
• 英文别名: 5-(furan-2-yl)isoxazole-3-carboxylic acid；5-furan-2-yl-isoxazole-3-carboxylic acid；5-[2]furyl-isoxazole-3-carboxylic acid；5-[2]Furyl-isoxazol-3-carbonsaeure；5-(2-Furyl)isoxazole-3-carboxylic acid
• CAS: 98434-06-1
• 化学式: C₈H₅NO₄
• mdl: MFCD04113954
• 分子量: 179.132
• InChiKey: MLWFYCMVBAIITM-UHFFFAOYSA-N

物化性质

• 熔点：
  151 °C
• 沸点：
  418.4±35.0 °C(Predicted)
• 密度：
  1.420±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.5
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S22,S26,S36/37/39
• 危险类别码：
  R36/37/38
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	5-(2-Furyl)isoxazole-3-carboxylic acid Material Safety Data Sheet
Synonym:
CAS:	98434-06-1

Section 1 - Chemical Product MSDS Name:5-(2-Furyl)isoxazole-3-carboxylic acid Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
98434-06-1	5-(2-Furyl)isoxazole-3-carboxylic acid	97+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 98434-06-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 148 - 149 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H5NO4
Molecular Weight: 179.13

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents, strong bases, amines.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 98434-06-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-(2-Furyl)isoxazole-3-carboxylic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 98434-06-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 98434-06-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 98434-06-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(2-呋喃)异恶唑-3-甲酸 在 叠氮磷酸二苯酯 、 三乙胺 、 水 作用下， 以 苯 为溶剂， 反应 2.0h， 以40%的产率得到5-(2-呋喃基)-1,2-恶唑-3-胺
  参考文献：
  名称：

  Isoxazole Derivatives and Use Thereof

  摘要：

  本文披露了异噁唑衍生物及其用途。作为Wnt的激动剂，异噁唑衍生物激活Wnt/β-连环蛋白信号传导，因此可用于治疗和预防与信号传导相关的疾病。此外，还披露了异噁唑衍生物的药用盐。

  公开号：

  US20090131336A1
• 作为产物：
  描述：

  5-(2-呋喃基)异恶唑-3-羧酸乙酯 在 lithium hydroxide 、 水 、 盐酸 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 15.0h， 以90%的产率得到5-(2-呋喃)异恶唑-3-甲酸
  参考文献：
  名称：

  Isoxazole Derivatives and Use Thereof

  摘要：

  本文披露了异噁唑衍生物及其用途。作为Wnt的激动剂，异噁唑衍生物激活Wnt/β-连环蛋白信号传导，因此可用于治疗和预防与信号传导相关的疾病。此外，还披露了异噁唑衍生物的药用盐。

  公开号：

  US20090131336A1

文献信息

• COMPOUNDS AND USES THEREOF
  申请人：Yumanity Therapeutics, Inc.

  公开号：US20190330198A1

  公开（公告）日：2019-10-31

  The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

  本发明涉及用于治疗神经系统疾病的化合物。本发明的化合物可以单独或与其他药用活性剂结合使用，用于治疗或预防神经系统疾病。
• Synthesis and structure–activity relationship study of pyrazolo[3,4- d ]pyrimidines as tyrosine kinase RET inhibitors
  作者：Chengyan Wang、Hongchun Liu、Zilan Song、Yinchun Ji、Li Xing、Xia Peng、Xisheng Wang、Jing Ai、Meiyu Geng、Ao Zhang

  DOI：10.1016/j.bmcl.2017.03.088

  日期：2017.6

  Three series of pyrazolo[3,4-d]pyrimidine derivatives were synthesized and evaluated as RET kinase inhibitors. Compounds 23a and 23c were identified to show significant activity both in the biochemical and the BaF3/CCDC6-RET cell assays. Compound 23c was found to significantly inhibit RET phosphorylation and down-stream signaling in BaF3/CCDC6-RET cells, confirming its potent cellular RET-targeting

  合成了三个系列的吡唑并[3,4-d]嘧啶衍生物，并作为RET激酶抑制剂进行了评估。化合物23a和23c在生化和BaF3 / CCDC6-RET细胞分析中均显示出显着活性。发现化合物23c在BaF3 / CCDC6-RET细胞中显着抑制RET磷酸化和下游信号传导，从而证实了其有效的细胞RET靶向特性。与具有严重毒性相关的对KDR具有相同效力的其他RET抑制剂不同，23c即使在1μM的浓度下也没有显示出显着的KDR抑制作用。这些结果证明23c是有效且选择性的RET抑制剂。
• [EN] ATF6 MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS ATF6 ET LEURS UTILISATIONS
  申请人：BLACK BELT TX LTD

  公开号：WO2021069721A1

  公开（公告）日：2021-04-15

  Compounds (1-2) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer. (Formula (1-2))

  提供了作为激活转录因子6（ATF6）调节剂的化合物（1-2）。这些化合物可能被用作治疗由ATF6介导的疾病或紊乱的治疗剂，并且可能特别适用于治疗病毒感染、神经退行性疾病、血管疾病或癌症。 （化学式（1-2））
• 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES
  申请人：Andreini Matteo

  公开号：US20110046122A1

  公开（公告）日：2011-02-24

  The present invention relates to 3-Amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明涉及具有BACE1和/或BACE2抑制活性的化学式I的3-氨基-5-苯基-5,6-二氢-2H-[1,4]噁嗪，以及它们的制备、含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗阿尔茨海默病和2型糖尿病等疾病方面具有用途。
• [EN] 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES<br/>[FR] DÉRIVÉS DE 3-AMINO-5-PHÉNYL-5,6-DIHYDRO-2H-[1,4]OXAZINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011020806A1

  公开（公告）日：2011-02-24

  The present invention relates to 3-Amino-5-phenyl-5,6-dihydro-2H-[l,4]oxazine derivatives of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明涉及具有BACE1和/或BACE2抑制活性的式(I)的3-氨基-5-苯基-5,6-二氢-2H-[1,4]噁嗪衍生物，其制备方法，含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗阿尔茨海默病和2型糖尿病等疾病方面是有用的。